White blood cells in the GI tract known as intraepithelial lymphocytes express the gamma delta T cell receptor (gamma delta IELs), which prevent infection and provide surveillance for the intestinal ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

A research team has uncovered abnormal immune cell function mechanisms that may lead to Crohn’s disease. Their discovery ...

New study shows that dysfunction of protective immune cells in GI tract may contribute to onset of inflammation in Crohn's disease.

Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biopharmaceutical company with a market capitalization of $65.5 million, focuses on developing engineered gamma-delta T cell therapies. The company ...

PLC ("TC BioPharm" or the "Company") (OTC: TCBPY) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce ...

Our novel gamma-delta T cell engager platform, presented for the first time at AACR 2025, demonstrates how we can combine the innate tumor-recognition capabilities of gamma-delta T cells with the ...

Poster Title: A novel gamma-delta T cell engager platform for cancer immunotherapy Session Title: Immunology/T Cell Engagers and Novel Antibody-Based Therapies Session Date and Time: Wednesday, April ...